Brief: Ocean Biomedical Announces Enrollment Of Patients For Phase 1b Study For Chronic Hepatitis B Treatment
17/10/2023 14:35
Oct 17 (Reuters) - Ocean Biomedical Inc OCEA.O :
* OCEAN BIOMEDICAL (NASDAQ: OCEA) ANNOUNCES ENROLLMENT OF
PATIENTS
FOR PHASE 1B STUDY FOR CHRONIC HEPATITIS B TREATMENT IN 50-50
JOINT VENTURE WITH VIRION THERAPEUTICS
Source text for Eikon: ID:nGNX5Cd10b
Further company coverage: OCEA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ocean Biomedical
See all newsTrump's shipbuilding plan could upend ocean cargo industry, companies warn
Brief: Ocean Biomedical Announces Breakthrough Findings In EGFR-Mutant Lung Cancer
Brief: Ocean Biomedical Announces Receipt Of Notice From Nasdaq Regarding Late Filing Of Quarterly Report On Form 10-Q
Brief: Ocean Biomedical receives Nasdaq staff determination letter
Brief: Ocean Biomedical- Ratified Fully Countersigned Copy Of Revised Agreement With Virion Therapeutics Received On Sept 26